Fig. 6

EZH2 down-regulates the expression of ABI3BP via H3K27 methylation. a, the relative expression of H3K27me3 determined by Western blot analysis following the treatment of GSK343 (EZH2 inhibitor) or sh-MALAT1. b, the relative expression of H3K27me3 determined by Western blot analysis following the treatment of UTX (histone demethylase). c, the relative expression of ABI3BP determined by Western blot analysis following the treatment of GSK343 (EZH2 inhibitor) or sh-MALAT1. d, the relative expression of ABI3BP determined by Western blot analysis following the treatment of UTX (histone demethylase). * p < 0.05 vs. the cells treated with sh-NC or DMSO. # p < 0.05 vs. the cells transfected with sh-MALAT1. The data was measurement data and expressed as mean value ± standard deviation. Comparison was analyzed by independent sample t-test between two groups and by one-way analysis of variance among multiple groups, followed by Turkey’s post-hoc test. The experiment was repeated 3 times. EZH2, enhancer of zeste homolog 2; ABI3BP, ABI family member 3 binding protein; H3K27me3, trimethylation of lysine 27 on histone H3 protein subunit; MALAT1, metastasis associated lung adenocarcinoma transcript 1; UTX, ubiquitously transcribed tetratricopeptide repeat on chromosome X; NC, negative control; DMSO, dimethyl sulfoxide